Radiation Oncology 101 this #NEETPG season for the uninitiated med student. Most MBBS grads in India come across #RadOnc for the very first time when preparing for NEETPG & a 4 hour lecture doesn't cut what we do in our sacred basements. Here is a primer to help you choose. 1/n
Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial @OncoAlert https://t.co/fiFLKKhBYV
Kidney SABR on the front cover of @TheLancetOncol. A well-deserved recognition for @_ShankarSiva for his work and efforts over the past 10+ years.
https://t.co/07jeA1lQMb
I just learned #cancer#surgical icon of the #nonoperativemanagement approach to #rectalcancer Dr. Angelita Habr-Gama just passed away today at the age of 93. She was AMAZING! She has changed our views on the necessity of surgery in the setting of cCR. #groundbreaking #cancerresearch #originaldisruptor
Deferring brain RT appeared “safe”overall:
•mOS 28.7 vs 23.3 mos
���HR 1.45, p=0.07
However, nearly HALF of pts in the delayed RT arm ultimately required salvage brain RT within 2 yrs (48% vs 21%).
Delayed RT patients more likely to need WBRT at progression (68% vs 54%)
#ASCO26
Proud to share ph III RCT on low-dose abiraterone (250 mg w/food) vs std-dose abi in CRPC.
Despite markedly lower drug exposure, low-dose abi had comparable efficacy, safety & QoL: supporting affordable and practical treatment https://t.co/hHmmLxM4hl
#ProstateCancer@OncoAlert
A personal story published today in the @TataMemorial Newsletter
Radiation after Cystectomy in Bladder Cancer (the BART trial): A Timeless Problem, A Timely Solution
Read Here:
https://t.co/bchheXlCU2
Introducing the Samvardhan Biodiversity and Conservation Fellowship — a 12-month Fellowship co-curated by Rohini Nilekani Philanthropies and Dasra, and seed funded by @RNP_Foundation, built to support the next generation of conservation leaders across India, especially those from grassroots communities and underrepresented regions.
Too many passionate conservationists leave the field not because they lose interest, but because the system doesn't support them. The Samvardhan Fellowship is here to change that.
What the fellowship offers:
- A seed grant of ₹3 lakh for practice-led conservation work
- Mentorship from conservation experts throughout the year
- Peer learning through cohort sessions, knowledge workshops, and community building
Who can apply:
- Early-career conservation researchers and practitioners under 35, engaged in public-interest conservation — whether in research, fieldwork, or community work.
- Applicants from diverse educational backgrounds and non-elite institutions are strongly encouraged. _(Note: PhD students are not eligible.)_
Applications are open now! Visit https://t.co/0FR75pzTd3 to apply.
14/The stakes are arithmetic. Full-dose pembro runs to six figures a year. This group's own framing: approved regimens reach 1–3% of patients in low- and middle-income countries.
There, dose is the entire access lever.
15/Why is this underestimated? Look at who's incentivized to shrink a dose.
The people who sell it have no reason to. De-escalation trials come from public hospitals and academics. The most important pricing experiment in oncology is run by the people with the least $.
Is SBRT (36.25 Gy/5#) non-inferior to MHRT in high-risk & N+ prostate cancer?
526 patients, 3 centres, mpMRI + PSMA staging, 77% whole-pelvis RT.
Largest RCT in this population. From @TataMemorial@RadOncTMC 🔥
#ESTRO2026
One of the standout talks of #ESTRO2026 👏 'A lot to be proud of'
@alison_tree brilliantly highlighted how modern #RadOnc in #PCa is evolving beyond technology alone , with increasing focus on continenze, sexual function and QoL alongside outstanding cancer control!
1/ Tremendous thanks to the patients, coauthors and all who made the EXTEND trial possible. The primary aggregated analysis is now available online @JCO_ASCO with ctDNA correlatives presented synchronously at @ESTRO_RT#ESTRO26
When I was a resident 24 years ago, we were taught that renal cancer is radiation resistant disease. Now, we learn that RT can achieve up to 100% local control when RT dose is appropriate.
New @JCO_ASCO * analysis of ~5,000 HCC patients treated with external beam radiation therapy across 30 centers in 11 countries.
Median overall survival:
-BCLC-0 (very early stage, a single tumor 2 cm or smaller): 6.8 years
-BCLC-A (early stage, single tumor of any size or up to 3 tumors ≤3 cm each): 4.6 years
-Treatment-naive BCLC-A: 5.4 years
Retrospective, but the scale is striking. EBRT belongs in the frontline HCC discussion.